Notice of Intent to Publish a Funding Opportunity Announcement for Trans-Agency Blood-Brain Interface Program (R61/R33 – Clinical Trials Not Allowed)

0
434

Opportunity ID: 313477
Opportunity Number: NOT-HL-19-682
Opportunity Title: Notice of Intent to Publish a Funding Opportunity Announcement for Trans-Agency Blood-Brain Interface Program (R61/R33 – Clinical Trials Not Allowed)
Opportunity Category: Discretionary
Opportunity Category Explanation:
Funding Instrument Type: Grant
Category of Funding Activity: Health
Category Explanation:
CFDA Number(s): 93.233
93.837
93.838
93.839
93.840
Eligible Applicants: State governments
County governments
City or township governments
Special district governments
Independent school districts
Public and State controlled institutions of higher education
Native American tribal governments (Federally recognized)
Public housing authorities/Indian housing authorities
Native American tribal organizations (other than Federally recognized tribal governments)
Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
Private institutions of higher education
For profit organizations other than small businesses
Small businesses
Others (see text field entitled “Additional Information on Eligibility” for clarification)
Additional Information on Eligibility:
Agency Code: HHS-NIH11
Agency Name: Department of Health and Human Services
National Institutes of Health
Posted Date: Mar 05, 2019
Last Updated Date: Mar 05, 2019
Estimated Synopsis Post Date: Jun 14, 2019
Fiscal Year: 2020
Award Ceiling:
Award Floor:
Estimated Total Program Funding:
Expected Number of Awards:
Description: The National Heart, Lung, and Blood Institute (NHLBI) in collaboration with the Department of Defense Joint Program Committee-6 (JPC-6), Combat Casualty Care Research Program (CCCRP) intends to promote a new initiative by publishing a Funding Opportunity Announcement (FOA). This FOA will establish a trans-agency program to support collaborations between hematologists/vascular experts, neuroscientists, and blood-brain barrier (BBB) tissue chip developers for high risk/high reward research to create enhanced/modified platforms that more closely model the human BBB. An improved human-like BBB prototype/model can serve as an invaluable resource to the scientific community, and complement BBB research currently based on animal models. The blood component has been a missing piece of the puzzle in blood-brain barrier research. This initiative intends to infuse the field with hematology, vascular, and circadian expertise to take translation in this area to the next step bringing the blood back to the blood-brain barrier. This Notice is being provided to allow potential applicants sufficient time to develop meaningful collaborations between hematologists/vascular experts, neuroscientists, and BBB tissue chip developers for responsive projects. The FOA is expected to be published in Summer 2019 with an expected application due date in Fall 2019. This FOA will utilize the R61/R33 activity code. Details of the planned FOA are provided below.
Version: 1





Visit the Official Webpage For More Details on Notice of Intent to Publish a Funding Opportunity Announcement for Trans-Agency Blood-Brain Interface Program (R61/R33 – Clinical Trials Not Allowed)

LEAVE A REPLY

Please enter your comment!
Please enter your name here